ReviewCurrent topics in behavioral neurosciences2022
Psychedelics in the Treatment of Headache and Chronic Pain Disorders.
Review in Current topics in behavioral neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology · 2025Review
- Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.British journal of pain · 2025Article
- From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.British journal of clinical pharmacology · 2024Review
- The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain.International journal of molecular sciences · 2024Article
- Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.Journal of pain research · 2024Article
- A narrative exploration of psilocybin's potential in mental health.Frontiers in psychiatry · 2024Review
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic potential of psychedelics in headache and chronic pain disorders is documented over decades of anecdotal and early investigational reports, which have paved the way for the first controlled studies of psilocybin and lysergic acid diethylamide (LSD) in these disorders. The reported lasting clinical effects after limited dosing with psychedelics present a novel means for disease management, but considerable further study will be required to address disease-specific treatments, uncover mechanism(s) of action, and verify safety. In this chapter, these topics are reviewed with particular attention to the neurobiological systems that offer potential sources of psychedelics' unique clinical effects in headache and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.